Samsung Bioepis Pushes Stelara Rival Into Phase I

Proposed Ustekinumab Biosimilar Is Competing With Several Other Candidates

 
• By David Wallace
  
Phase One 1 Blocks
Samsung Bioepis’ SB17 ustekinumab biosimilar has started Phase I trials • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products